Dimerix (DXB) is a drug development company with a platform that can identify druggable receptor combinations to treat diseases. DXB has two indications in the clinic, a Phase 2 study testing a drug for diabetic kidney disease and a Phase 2a study targeting the rare kidney disease focal segmental glomerulosclerosis (FSGS) for which it has been awarded Orphan Drug Status in both U.S. and Europe. Readout of results is expected mid-year. We initiate with a SPEC BUY recommendation and a price target of $0.40 p/s.
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.